Critical Analysis: EDAP TMS (EDAP) and LeMaitre Vascular (LMAT)
EDAP TMS (NASDAQ: EDAP) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.
Valuation & Earnings
This table compares EDAP TMS and LeMaitre Vascular’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|EDAP TMS||$44.00 million||2.04||$270,377.00||($0.01)||-309.69|
|LeMaitre Vascular||$96.40 million||7.57||$23.12 million||$0.69||55.61|
LeMaitre Vascular has higher revenue and earnings than EDAP TMS. EDAP TMS is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
9.4% of EDAP TMS shares are held by institutional investors. Comparatively, 66.8% of LeMaitre Vascular shares are held by institutional investors. 23.7% of LeMaitre Vascular shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares EDAP TMS and LeMaitre Vascular’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and price targets for EDAP TMS and LeMaitre Vascular, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
EDAP TMS presently has a consensus price target of $6.50, suggesting a potential upside of 109.68%. LeMaitre Vascular has a consensus price target of $30.50, suggesting a potential downside of 20.51%. Given EDAP TMS’s stronger consensus rating and higher possible upside, research analysts clearly believe EDAP TMS is more favorable than LeMaitre Vascular.
LeMaitre Vascular pays an annual dividend of $0.22 per share and has a dividend yield of 0.6%. EDAP TMS does not pay a dividend. LeMaitre Vascular pays out 31.9% of its earnings in the form of a dividend.
Volatility and Risk
EDAP TMS has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.
LeMaitre Vascular beats EDAP TMS on 11 of the 15 factors compared between the two stocks.
EDAP TMS Company Profile
EDAP TMS S.A. (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors. The Company also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) and distributes other types of urology devices in certain countries. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the invasive treatment of urological and other clinical indications. The UDS division is engaged in the development, marketing, manufacturing and servicing of medical devices for the invasive diagnosis or treatment of urological disorders, urinary stones, and other clinical indications.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.
Receive News & Ratings for EDAP TMS S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EDAP TMS S.A. and related companies with MarketBeat.com's FREE daily email newsletter.